Nuclear factor-kappa B inhibition can enhance therapeutic efficacy of 131I on the in vivo management of differentiated thyroid cancer

Life Sciences

Volumn 91, Issue 23-24, 2012, Pages 1236-1241

  Meng, Zhaowei ^a   Lou, Shanshan ^a,b   Tan, Jian ^a   Xu, Ke ^a   Jia, Qiang ^a   Zheng, Wei ^a   Wang, Shen ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b TIANJIN NORMAL UNIVERSITY   (China)

Author keywords

Differentiated thyroid cancer; Nuclear factor kappa B; Radioiodine 131 therapy; Therapeutic efficacy

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IODINE 131; PERTECHNETIC ACID TC 99M;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER SIZE; CONTROLLED STUDY; DIFFERENTIATED THYROID CANCER; DNA BINDING; DRUG EFFICACY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MONOTHERAPY; MOUSE; NICK END LABELING; NONHUMAN; PROTEIN EXPRESSION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CHEMORADIOTHERAPY; IN SITU NICK-END LABELING; IODINE RADIOISOTOPES; MICE; MICE, NUDE; NF-KAPPA B; NITRILES; SULFONES; THYROID NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME;

MUS; MUS MUSCULUS;

EID: 84869505569     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2012.09.026     Document Type: Article

References (57)

1. C. Als, P. Gedeon, H. Rosler, C. Minder, P. Netzer, and J.A. Laissue Survival analysis of 19 patients with toxic thyroid carcinoma J Clin Endocrinol Metab 87 2002 4122 4127
2. S. Basaria, and R. Salvatori Thyrotoxicosis due to metastatic papillary thyroid cancer in a patient with Graves' disease J Endocrinol Invest 25 2002 639 642
3. D.S. Basseres, and A.S. Baldwin Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression Oncogene 25 2006 6817 6830
4. V. Baud, and M. Karin Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls Nat Rev Drug Discov 8 2009 33 40
5. M.M. Chaturvedi, B. Sung, V.R. Yadav, R. Kannappan, and B.B. Aggarwal NF-kappaB addiction and its role in cancer: 'one size does not fit all' Oncogene 30 2011 1615 1630
6. D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, and S.J. Mandel Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer Thyroid 19 2009 1167 1214
7. Y. Dai, M. Liu, W. Tang, J. DeSano, E. Burstein, and M. Davis Molecularly targeted radiosensitization of human prostate cancer by modulating inhibitor of apoptosis Clin Cancer Res 14 2008 7701 7710
8. D. Dingli, R.M. Diaz, E.R. Bergert, M.K. O'Connor, J.C. Morris, and S.J. Russell Genetically targeted radiotherapy for multiple myeloma Blood 102 2003 489 496
9. D. Dingli, K.W. Peng, M.E. Harvey, P.R. Greipp, M.K. O'Connor, and R. Cattaneo Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter Blood 103 2004 1641 1646
10. C. Durante, N. Haddy, E. Baudin, S. Leboulleux, D. Hartl, and J.P. Travagli Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy J Clin Endocrinol Metab 91 2006 2892 2899
11. R.M. Dwyer, E.R. Bergert, M.K. O'Connor, S.J. Gendler, and J.C. Morris In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter Clin Cancer Res 11 2005 1483 1489
12. R.M. Dwyer, E.R. Bergert, M.K. O'Connor, S.J. Gendler, and J.C. Morris Adenovirus-mediated and targeted expression of the sodium-iodide symporter permits in vivo radioiodide imaging and therapy of pancreatic tumors Hum Gene Ther 17 2006 661 668
13. R.M. Dwyer, E.R. Bergert, M.K. O'Connor, S.J. Gendler, and J.C. Morris Sodium iodide symporter-mediated radioiodide imaging and therapy of ovarian tumor xenografts in mice Gene Ther 13 2006 60 66
14. R.O. Escarcega, S. Fuentes-Alexandro, M. Garcia-Carrasco, A. Gatica, and A. Zamora The transcription factor nuclear factor-kappa B and cancer Clin Oncol (R Coll Radiol) 19 2007 154 161
15. F. Furuya, H. Shimura, H. Suzuki, K. Taki, K. Ohta, and K. Haraguchi Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin Endocrinology 145 2004 2865 2875
16. H. Gharib, E. Papini, R. Paschke, D.S. Duick, R. Valcavi, and L. Hegedus American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association Medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: executive summary of recommendations Endocr Pract 16 2010 468 475
17. V. Gossye, G. Haegeman, and K. De Bosscher Therapeutic implications of the nuclear factor-kappaB/nuclear receptor cross-talk Front Biosci 13 2008 4122 4143
18. S.I. Grivennikov, and M. Karin Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer Cytokine Growth Factor Rev 21 2010 11 19
19. U. Haberkorn, P. Beuter, W. Kubler, H. Eskerski, M. Eisenhut, and R. Kinscherf Iodide kinetics and dosimetry in vivo after transfer of the human sodium iodide symporter gene in rat thyroid carcinoma cells J Nucl Med 45 2004 827 833
20. Y.J. Hsieh, C.C. Ke, R.S. Liu, F.H. Wang, K.T. Tang, and C.W. Chi Radioiodide imaging and treatment of ARO cancer xenograft in a mouse model after expression of human sodium iodide symporter Anticancer Res 27 2007 2515 2522
21. M. Karin Nuclear factor-kappaB in cancer development and progression Nature 441 2006 431 436
22. A. Katsman, K. Umezawa, and B. Bonavida Chemosensitization and immunosensitization of resistant cancer cells to apoptosis and inhibition of metastasis by the specific NF-kappaB inhibitor DHMEQ Curr Pharm Des 15 2009 792 808
23. S.A. Keller, D. Hernandez-Hopkins, J. Vider, V. Ponomarev, E. Hyjek, and E.J. Schattner NF-kappaB is essential for the progression of KSHV- and EBV-infected lymphomas in vivo Blood 107 2006 3295 3302
24. M.K. Kim, Y.K. Jeon, J.K. Woo, Y. Choi, D.H. Choi, and Y.H. Kim The C-terminal region of Bfl-1 sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis by suppressing NF-kappaB activity and down-regulating Bfl-1 Mol Cancer 10 2011 98
25. A.B. Kunnumakkara, S. Guha, S. Krishnan, P. Diagaradjane, J. Gelovani, and B.B. Aggarwal Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products Cancer Res 67 2007 3853 3861
26. Y.C. Kuo, W.C. Lin, I.T. Chiang, Y.F. Chang, C.W. Chen, and S.H. Su Sorafenib sensitizes human colorectal carcinoma to radiation via suppression of NF-kappaB expression in vitro and in vivo Biomed Pharmacother 66 2012 12 20
27. F. Li, and G. Sethi Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy Biochim Biophys Acta 1805 2010 167 180
28. Y.C. Liu, I.T. Chiang, F.T. Hsu, and J.J. Hwang Using NF-kappaB as a molecular target for theranostics in radiation oncology research Expert Rev Mol Diagn 12 2012 139 146
29. M. Malehmir, V. Haghpanah, B. Larijani, S. Ahmadian, K. Alimoghaddam, and R. Heshmat Multifaceted suppression of aggressive behavior of thyroid carcinoma by all-trans retinoic acid induced re-differentiation Mol Cell Endocrinol 348 2012 260 269
30. E.L. Mazzaferri, and R.T. Kloos Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer J Clin Endocrinol Metab 86 2001 1447 1463
31. Z. Meng, N. Mitsutake, M. Nakashima, D. Starenki, M. Matsuse, and S. Takakura Dehydroxymethylepoxyquinomicin, a novel nuclear Factor-kappaB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells Endocrinology 149 2008 5357 5365
32. Z. Meng, S. Lou, J. Tan, K. Xu, Q. Jia, and W. Zheng Nuclear factor-kappa B inhibition can enhance apoptosis of differentiated thyroid cancer cells induced by I PLoS One 7 2012 e33597
33. E. Mitrofanova, R. Unfer, N. Vahanian, W. Daniels, E. Roberson, and T. Seregina Rat sodium iodide symporter for radioiodide therapy of cancer Clin Cancer Res 10 2004 6969 6976
34. A. Miyauchi, Y. Takamura, Y. Ito, A. Miya, K. Kobayashi, and F. Matsuzuka 3,5,3′-Triiodothyronine thyrotoxicosis due to increased conversion of administered levothyroxine in patients with massive metastatic follicular thyroid carcinoma J Clin Endocrinol Metab 93 2008 2239 2242
35. T. Mukogawa, F. Koyama, M. Tachibana, A. Takayanagi, N. Shimizu, and H. Fujii Adenovirus-mediated gene transduction of truncated I kappa B alpha enhances radiosensitivity in human colon cancer cells Cancer Sci 94 2003 745 750
36. S. Olivier, P. Robe, and V. Bours Can NF-kappaB be a target for novel and efficient anti-cancer agents? Biochem Pharmacol 72 2006 1054 1068
37. F. Pacifico, and A. Leonardi Role of NF-kappaB in thyroid cancer Mol Cell Endocrinol 321 2010 29 35
38. F. Pacini, M.G. Castagna, L. Brilli, and G. Pentheroudakis Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 21 Suppl. 5 2010 v214 v219
39. I. Palona, H. Namba, N. Mitsutake, D. Starenki, A. Podtcheko, and I. Sedliarou BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation Endocrinology 147 2006 5699 5707
40. D.G. Pfister, and J.A. Fagin Refractory thyroid cancer: a paradigm shift in treatment is not far off J Clin Oncol 26 2008 4701 4704
41. S. Prasad, J. Ravindran, and B.B. Aggarwal NF-kappaB and cancer: how intimate is this relationship Mol Cell Biochem 336 2010 25 37
42. K.M. Rahman, F.H. Sarkar, S. Banerjee, Z. Wang, D.J. Liao, and X. Hong Therapeutic intervention of experimental breast cancer bone metastasis by indole-3-carbinol in SCID-human mouse model Mol Cancer Ther 5 2006 2747 2756
43. F. Rosario, A.R. Marques, L. Roque, R. Rodrigues, T.C. Ferreira, and E. Limbert Metastatic follicular carcinoma associated with hyperthyroidism Clin Nucl Med 30 2005 79 82
44. C. Shimada, Y. Ninomiya, E. Suzuki, and K. Umezawa Efficient cellular uptake of the novel NF-kappaB inhibitor (-)-DHMEQ and irreversible inhibition of NF-kappaB in neoplastic cells Oncol Res 18 2010 529 535
45. H. Shimura, K. Haraguchi, A. Miyazaki, T. Endo, and T. Onaya Iodide uptake and experimental 131I therapy in transplanted undifferentiated thyroid cancer cells expressing the Na +/I- symporter gene Endocrinology 138 1997 4493 4496
46. J.W. Smit, J.P. Schroder-van der Elst, M. Karperien, I. Que, M. Stokkel, and D. van der Heide Iodide kinetics and experimental (131)I therapy in a xenotransplanted human sodium-iodide symporter-transfected human follicular thyroid carcinoma cell line J Clin Endocrinol Metab 87 2002 1247 1253
47. C. Spitzweg, M.K. O'Connor, E.R. Bergert, D.J. Tindall, C.Y. Young, and J.C. Morris Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter Cancer Res 60 2000 6526 6530
48. C. Spitzweg, A.B. Dietz, M.K. O'Connor, E.R. Bergert, D.J. Tindall, and C.Y. Young In vivo sodium iodide symporter gene therapy of prostate cancer Gene Ther 8 2001 1524 1531
49. D. Starenki, H. Namba, V. Saenko, A. Ohtsuru, and S. Yamashita Inhibition of nuclear factor-kappaB cascade potentiates the effect of a combination treatment of anaplastic thyroid cancer cells J Clin Endocrinol Metab 89 2004 410 418
50. D.V. Starenki, H. Namba, V.A. Saenko, A. Ohtsuru, S. Maeda, and K. Umezawa Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin Clin Cancer Res 10 2004 6821 6829
51. T. Takano, A. Miyauchi, Y. Ito, and N. Amino Thyroxine to triiodothyronine hyperconversion thyrotoxicosis in patients with large metastases of follicular thyroid carcinoma Thyroid 16 2006 615 618
52. T. Tamatani, M. Azuma, K. Motegi, N. Takamaru, Y. Kawashima, and T. Bando Cepharanthin-enhanced radiosensitivity through the inhibition of radiation-induced nuclear factor-kappaB activity in human oral squamous cell carcinoma cells Int J Oncol 31 2007 761 768
53. J. Tan, G. Zhang, W. Xu, Z. Meng, F. Dong, and F. Zhang Thyrotoxicosis due to functioning metastatic follicular thyroid carcinoma after twelve I-131 therapies Clin Nucl Med 34 2009 615 619
54. K. Umezawa Inhibition of tumor growth by NF-kappaB inhibitors Cancer Sci 97 2006 990 995
55. R. Voboril, and J. Weberova-Voborilova Constitutive NF-kappaB activity in colorectal cancer cells: impact on radiation-induced NF-kappaB activity, radiosensitivity, and apoptosis Neoplasma 53 2006 518 523
56. P. Wang, Z. Meng, J. Tan, Q. Jia, and F. Zhang An improved method for measurement of target-to-background ratio in assessing mediastinal lesions on 18F-FDG coincidence SPECT/CT imaging Nucl Med Commun 31 2010 398 404
57. X. Zheng, R.L. Chang, X.X. Cui, G. Avila, M.T. Huang, and Y. Liu Inhibition of NF-kappaB by (E)3-[(4-methylphenyl)-sulfonyl]-2-propenenitrile (BAY11-7082; BAY) is associated with enhanced 12-O-tetradecanoylphorbol-13- acetate-induced growth suppression and apoptosis in human prostate cancer PC-3 cells Int J Oncol 32 2008 257 264